Flunixin meglumine USP37 42461-84-7 Flunixin meglumin

Product no. chemwillFME1021

Flunixin meglumine USP37 42461-84-7 Flunixin meglumin

USP37 GMP factory

Flunixin Meglumine 42461-84-7 Pharmaceutical Raw Materials

Flunixin Meglumine 42461-84-7 Pharmaceutical Intermediate

Flunixin Meglumine 42461-84-7  Raw Chemical Product

Flunixin Meglumine 42461-84-7 Supplier & manufactuer

Appearance     White Crystalline powder    
Identification     1) The IR absorption spectrum of the sample is concordant with that of Flunixin meglumine reference standard.
2) The retention times of main peak in the Chromatogram of Assay preparation corresponds to that in the Chromatogram of the Standard preparation,as obtained in the Assay
3)  Ultraviolet absorption: 197U.As per USP standard    

Melting Point    137 ~ 140℃    137.5 ~ 138.50℃
Specific rotation    -9 ~ -12°    -11.5°
Residue on ignition    ≤0.20%    0.09%
pH Value    7.0 ~ 9.0    8.8
Loss on drying    ≤0.50%    0.29%
Heavy Metals    ≤10ppm    

comply with  usp37/  ep8  /bpv2012

highly quality and immedaite delivery

package: 25.0kg net drum

main uses: mammalian anti-inflammatory analgesia, can alleviate muscle abnormalities caused by inflammation and pain, treatment of diarrhea, tremor, colitis, respiratory diseases, endotoxin-induced mastitis, arthritis, fever, diarrhea, tremor, eye infections, etc.        

Route of synthesis

Flunixin meglumine Basic information
Product Name:    Flunixin meglumine
Synonyms:    Flunixin meglumine for veterinary use;FLUNIXIN MEGLUMINE;Flunixin Meglunine;2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylate, 1-deoxy-1-(methylamino)-D-glucitol(1:1);Flunixin Solution, 100ppm;Flunixin Meglumine injectable grade;Flunixin meglumine, 98.5%;1-deoxy-1-(methylamino)-d-glucito2-((2-methyl-3-(trifluoromethyl)phenyl)am
CAS:    42461-84-7
MF:    C21H28F3N3O7
MW:    491.46
EINECS:    255-836-0
Product Categories:    -;veterinary drugs;Aromatics;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API
Mol File:    42461-84-7.mol
Flunixin meglumine Structure
Flunixin meglumine Chemical Properties
Melting point     136.6-137.4 °C
alpha     -9～-12゜(D/20℃)(c=12,CH3OH)
storage temp.     0-6°C
solubility     H2O: freely soluble
form     solid
color     off-white
Water Solubility     soluble
Safety Information
Hazard Codes     Xi
Risk Statements     36/37/38
Safety Statements     26-36
RIDADR     UN 2811 6.1 / PGI
WGK Germany     3
RTECS     LZ4367000
HS Code     29339900
MSDS Information
Provider    Language
SigmaAldrich     English
Flunixin meglumine Usage And Synthesis
Chemical Properties    White Solid
Uses    dental carries prophylactic
Uses    Cyclooxigenase inhibitor. Anti-inflammatory; analgesic; antipyretic.
Definition    ChEBI: An organoammonium salt obtained by combining flunixin with one molar equivalent of 1-deoxy-1-(methylamino)-D-glucitol. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic propert es; used in veterinary medicine for treatment of horses, cattle and pigs.
Brand name    Banamine Veterinary (Schering-Plough Animal Health).
Veterinary Drugs and Treatments    In the United States, flunixin meglumine is approved for use in horses, cattle and swine; however, it is approved for use in dogs in other countries. The approved indications for its use in the horse are for the alleviation of inflammation and pain associated with musculoskeletal disorders and alleviation of visceral pain associated with colic. In cattle it is approved for the control of pyrexia associated with bovine respiratory disease and endotoxemia, and control of inflammation in endotoxemia. In swine, flunixin is approved for use to control pyrexia associated with swine respiratory disease.
Flunixin has been suggested for many other indications in various species, including: Horses: foal diarrheas, shock, colitis, respiratory disease, post-race treatment, and pre- and post ophthalmic and general surgery; Dogs: disk problems, arthritis, heat stroke, diarrhea, shock, ophthalmic inflammatory conditions, pre- and post ophthalmic and general surgery, and treatment of parvovirus infection; Cattle: acute respiratory disease, acute coliform mastitis with endotoxic shock, pain (downer cow), and calf diarrheas; Swine: agalactia/hypogalactia, lameness, and piglet diarrhea. It should be noted that the evidence supporting some of these indications is equivocal and flunixin may not be appropriate for every case.
Flunixin meglumine Preparation Products And Raw materials